TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock News

USA - Nasdaq - NASDAQ:TNXP - US8902608392 - Common Stock

19.64 USD

+0.11 (+0.56%)

Last: 12/5/2025, 8:00:01 PM

19.88 USD

+0.24 (+1.22%)

After Hours: 12/5/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

TNXP Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: BioMedWire - Mentions: SNGX AMGN FOLD CTOR

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

12 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

19 days ago - By: Stocktwits

Why Did TNXP Stock Jump 10% Today?

17 days ago - By: Stocktwits

Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’

19 days ago - By: Benzinga

Why Tonix Pharmaceuticals (TNXP) Stock Jumped Monday Morning

19 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

25 days ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

4 months ago - By: Stocktwits - Mentions: UWM IWMW

News Image

This Pharma Stock Shot Up 4% Pre-Market After FDA Approval For Drug, Retail’s Super Bullish But Believes ‘This Is A Marathon, Not A Sprint’

4 months ago - By: Stocktwits

News Image

Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

a month ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

2 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

3 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

3 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

4 months ago - By: Benzinga - Mentions: FN AGRO XNET PGEN ...

Fabrinet, Adecoagro And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

4 months ago - By: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia